Eli Lilly Stock a Buy After FDA Signs Off on New Weight-Loss Drug? Hosted by Laycee KluinNovember 28, 2023 ShareLink copied to clipboard. Play video for Eli Lilly Stock a Buy After FDA Signs Off on New Weight-Loss Drug?DetailsGuestsIn this video, we dive into the evolving pharmaceutical landscape with Dylan Jovine from Behind the Markets. We unpack the explosive growth expected in the weight loss drug industry, projected to hit a whopping $150-200 billion by 2030. There are major players strategically positioning themselves in this market, and we'll uncover the intense competition between giants like Novo Nordisk and Eli Lilly, fighting for dominance with their groundbreaking weight loss drugs. Plus, discover the potential impact on stock values and the healthcare industry as a whole. We'll also discuss the critical phase transitions in FDA drug approval, spotting opportunities, and why investing in biotech has Dylan so bullish on its future.Read Ozempic vs. Mounjaro:: Battle of the bulgeStocks Mentioned in This EpisodeCompanyMarketRank™Current PriceDividend YieldP/E RatioLLYEli Lilly and Company4.8312 of 5 stars$841.70+14.5%0.71%71.88NVONovo Nordisk A/S4.617 of 5 stars$57.99-7.8%2.81%17.63 Compare These Stocks Add These Stocks to My Watchlist Laycee Kluin, HostDigital Marketing Strategist, MarketBeatAs MarketBeat's Digital Marketing Strategist, Laycee helps with the marketing side of tasks including developing email campaigns, running the promotion of the MarketBeat products and exploring social media opportunities. She felt called to the Marketing industry because she enjoys collaborating with people and making connections. The University of Sioux Falls alum majored in Media Studies with minors in Communications and Spanish. Laycee brings a background in Financial Services Marketing.Previous VideoAll VideosNext Video Subscribe on YouTube Don't Miss a Video Subscribe to watch the latest stock market videos from MarketBeat. We empower investors to make better trading decisions by providing real-time financial data and objective market analysis. Subscribe on YouTube More From MarketBeat🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored10 Best Small Cap Stocks to Buy NowLet's talk about small cap stocks. It's common knowledge that tilting your stock portfolio toward smaller-capi...MarketBeatHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | Sponsored12 Cannabis Stocks to Buy NowSlowly and surely the cannabis industry is becoming mainstream. As more states legalize medical and recreation...MarketBeatMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored7 Growth Stocks Positioned for Further Growth In 2023 and 2024, the stock market outperformed analyst expectations, with the S&P 500 index gaining ove...MarketBeat Listen to MarketBeat Other Platforms Recent Videos Featured Articles and OffersGold Rally Continues: These 3 Mining Stocks Are Likely to BenefitApril 16, 2025View Gold Rally Continues: These 3 Mining Stocks Are Likely to Benefit‘Wheels Are Falling Off’ the U.S. Stock MarketFrom Stansberry Research(Ad)View ‘Wheels Are Falling Off’ the U.S. Stock MarketWhy NVIDIA Stock Could Soar Despite Wall Street DowngradesApril 14, 2025View Why NVIDIA Stock Could Soar Despite Wall Street DowngradesTesla Stock Eyes Breakout With Earnings on DeckApril 16, 2025View Tesla Stock Eyes Breakout With Earnings on Deck3 Stocks Upping Dividends & 1 With A 10% Special Dividend YieldApril 16, 2025View 3 Stocks Upping Dividends & 1 With A 10% Special Dividend YieldElon Set to Shock the World by May 1st ?From Brownstone Research(Ad)View Elon Set to Shock the World by May 1st ? Search Headlines Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Hosted by Laycee KluinNovember 28, 2023 ShareLink copied to clipboard. Play video for Eli Lilly Stock a Buy After FDA Signs Off on New Weight-Loss Drug?DetailsGuestsIn this video, we dive into the evolving pharmaceutical landscape with Dylan Jovine from Behind the Markets. We unpack the explosive growth expected in the weight loss drug industry, projected to hit a whopping $150-200 billion by 2030. There are major players strategically positioning themselves in this market, and we'll uncover the intense competition between giants like Novo Nordisk and Eli Lilly, fighting for dominance with their groundbreaking weight loss drugs. Plus, discover the potential impact on stock values and the healthcare industry as a whole. We'll also discuss the critical phase transitions in FDA drug approval, spotting opportunities, and why investing in biotech has Dylan so bullish on its future.Read Ozempic vs. Mounjaro:: Battle of the bulgeStocks Mentioned in This EpisodeCompanyMarketRank™Current PriceDividend YieldP/E RatioLLYEli Lilly and Company4.8312 of 5 stars$841.70+14.5%0.71%71.88NVONovo Nordisk A/S4.617 of 5 stars$57.99-7.8%2.81%17.63 Compare These Stocks Add These Stocks to My Watchlist Laycee Kluin, HostDigital Marketing Strategist, MarketBeatAs MarketBeat's Digital Marketing Strategist, Laycee helps with the marketing side of tasks including developing email campaigns, running the promotion of the MarketBeat products and exploring social media opportunities. She felt called to the Marketing industry because she enjoys collaborating with people and making connections. The University of Sioux Falls alum majored in Media Studies with minors in Communications and Spanish. Laycee brings a background in Financial Services Marketing.Previous VideoAll VideosNext Video Subscribe on YouTube Don't Miss a Video Subscribe to watch the latest stock market videos from MarketBeat. We empower investors to make better trading decisions by providing real-time financial data and objective market analysis. Subscribe on YouTube More From MarketBeat🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored10 Best Small Cap Stocks to Buy NowLet's talk about small cap stocks. It's common knowledge that tilting your stock portfolio toward smaller-capi...MarketBeatHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | Sponsored12 Cannabis Stocks to Buy NowSlowly and surely the cannabis industry is becoming mainstream. As more states legalize medical and recreation...MarketBeatMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored7 Growth Stocks Positioned for Further Growth In 2023 and 2024, the stock market outperformed analyst expectations, with the S&P 500 index gaining ove...MarketBeat
